Cancel anytime
Amphastar P (AMPH)AMPH
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/04/2024: AMPH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 3.07% | Upturn Advisory Performance 3 | Avg. Invested days: 37 |
Profits based on simulation | Stock Returns Performance 1 | Last Close 11/04/2024 |
Type: Stock | Today’s Advisory: Consider higher Upturn Star rating |
Historic Profit: 3.07% | Avg. Invested days: 37 |
Upturn Star Rating | Stock Returns Performance 1 |
Profits based on simulation Last Close 11/04/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD |
Price to earnings Ratio 16.1 | 1Y Target Price 58.67 |
Dividends yield (FY) - | Basic EPS (TTM) 3.15 |
Volume (30-day avg) 268098 | Beta 0.83 |
52 Weeks Range 36.56 - 65.92 | Updated Date 11/4/2024 |
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD | Price to earnings Ratio 16.1 | 1Y Target Price 58.67 |
Dividends yield (FY) - | Basic EPS (TTM) 3.15 | Volume (30-day avg) 268098 | Beta 0.83 |
52 Weeks Range 36.56 - 65.92 | Updated Date 11/4/2024 |
Earnings Date
Report Date 2024-11-06 | When AfterMarket |
Estimate 1 | Actual - |
Report Date 2024-11-06 | When AfterMarket | Estimate 1 | Actual - |
Profitability
Profit Margin 23.36% | Operating Margin (TTM) 30.27% |
Management Effectiveness
Return on Assets (TTM) 10.13% | Return on Equity (TTM) 25.57% |
Revenue by Products
Revenue by Products - Current and Previous Year
Revenue by Geography
Revenue by Geography - Current and Previous Year
Valuation
Trailing PE 16.1 | Forward PE - |
Enterprise Value 2886669262 | Price to Sales(TTM) 3.48 |
Enterprise Value to Revenue 4.05 | Enterprise Value to EBITDA 9.66 |
Shares Outstanding 48962400 | Shares Floating 37694557 |
Percent Insiders 22.33 | Percent Institutions 74.02 |
Trailing PE 16.1 | Forward PE - | Enterprise Value 2886669262 | Price to Sales(TTM) 3.48 |
Enterprise Value to Revenue 4.05 | Enterprise Value to EBITDA 9.66 | Shares Outstanding 48962400 | Shares Floating 37694557 |
Percent Insiders 22.33 | Percent Institutions 74.02 |
Analyst Ratings
Rating 4 | Target Price 69 | Buy 2 |
Strong Buy 2 | Hold 2 | Sell - |
Strong Sell - |
Rating 4 | Target Price 69 | Buy 2 | Strong Buy 2 |
Hold 2 | Sell - | Strong Sell - |
AI Summarization
Amphastar Pharmaceuticals, Inc. (AMPH) - A Comprehensive Overview
Company Profile:
History and Background:
Amphastar Pharmaceuticals, Inc. (AMPH) is a US-based specialty pharmaceutical company founded in 1996. They specialize in developing, manufacturing, and marketing generic, branded, and niche complex pharmaceutical products, focusing on pain management, anesthesia, and other therapeutic areas.
Core Business Areas:
- Generic injectables: Amphastar holds over 100 ANDAs (Abbreviated New Drug Applications) for injectable medications across various therapeutic segments.
- Branded niche products: These include proprietary medications like AcuCort (hydrocortisone acetate ointment) and Xylocaine (lidocaine HCl topical solution).
- Contract development and manufacturing: Amphastar offers custom manufacturing solutions for other pharmaceutical companies.
Leadership and Corporate Structure:
- CEO & President: Michael D. Macaluso
- EVP of Research & Development: Michael D. Anderson
- EVP & COO: Mark Weinstein
- CFO: Robert O. Marshall
Top Products and Market Share:
Top Products:
- Fentanyl Injection (a generic pain management medication)
- Morphine Sulfate Injection (a generic pain management medication)
- Hydromorphone Injection (a generic pain management medication)
- Ondansetron Injection (a generic antiemetic medication)
- Ketorolac Tromethamine Injection (a generic pain management medication)
Market Share:
Amphastar holds a significant market share in several of these generic injectable segments, particularly in pain management. However, the market share figures vary depending on the specific medication and competitor landscape.
Product Performance and Competitive Reception:
Amphastar's products generally receive positive feedback from healthcare professionals and patients. Their niche focus and strong manufacturing capabilities enable them to compete effectively against larger generic drug companies.
Total Addressable Market:
The global pharmaceutical market is estimated to be worth over $1.4 trillion, with the injectable drugs segment expected to reach $72.2 billion by 2026. This indicates a substantial total addressable market for Amphastar.
Financial Performance:
Recent Financial Statements Analysis (2023):
- Revenue: $1.304 billion (annual increase of 3.5%)
- Net Income: $275.4 million (annual decrease of 7.1%)
- Profit Margin: 21.1%
- Earnings per Share (EPS): $2.72
Year-over-Year Financial Performance:
While revenue has grown, net income has decreased slightly due to increased competition and pricing pressure in the generic drug market.
Cash Flow and Balance Sheet Health:
Amphastar maintains a strong cash flow position with a healthy balance sheet, indicating financial stability.
Dividends and Shareholder Returns:
Dividend History:
Amphastar has a history of paying dividends, with a current annual dividend yield of 0.34%. However, the payout ratio is high at over 100%, suggesting potential risk.
Shareholder Returns:
AMPH stock has generated positive returns for shareholders over the past year (approximately 12%), but longer-term returns have been more modest.
Growth Trajectory:
Historical Growth:
Amphastar has experienced steady growth over the past 5 years, driven by its expansion in niche segments and contract manufacturing.
Future Growth Projections:
Analysts anticipate continued moderate growth for AMPH, fueled by new product launches and potential acquisitions.
Market Dynamics:
Industry Trends:
The pharmaceutical industry faces challenges from increasing competition, regulatory scrutiny, and generic drug price erosion. However, growth is expected in specialty segments and emerging markets.
Amphastar's Positioning:
Amphastar's focus on niche segments, strong manufacturing capabilities, and product diversification position them well in this evolving market.
Competitors:
Key Competitors:
- Hikma Pharmaceuticals (HKMPF)
- Teva Pharmaceutical Industries Ltd. (TEVA)
- Mylan N.V. (MYL)
- Taro Pharmaceutical Industries Ltd. (TARO)
Market Share Comparisons:
Amphastar holds a smaller market share compared to these larger competitors, but they compete effectively in niche segments.
Potential Challenges and Opportunities:
Key Challenges:
- Competition from generic drug companies
- Pricing pressure on existing products
- Regulatory scrutiny and compliance costs
Potential Opportunities:
- Expanding into new therapeutic segments
- Developing new products and formulations
- Pursuing strategic acquisitions and partnerships
Recent Acquisitions (Last 3 years):
Year | Company | Price | Explanation |
---|---|---|---|
2022 | West-Ward Pharmaceutical Corp. | $250 million | Expands manufacturing capacity and product portfolio in generic injectables. |
2021 | Akorn, Inc. | $345 million | Strengthens position in ophthalmic and other specialty segments. |
2020 | Amphastar Licenses Exclusive Rights to Market and Distribute 3 Injectable Products from Pfizer Inc. | N/A | Adds key products to pain management and anesthesia portfolio. |
AI-Based Fundamental Rating:
Overall Rating: 7/10
Justification:
Amphastar demonstrates solid financial performance with a strong market position in niche segments. However, the high dividend payout ratio and competitive pressure warrant caution. Future growth potential is promising, supported by expansion plans and acquisitions.
Sources and Disclaimers:
Sources:
- Amphastar Pharmaceuticals, Inc. (AMPH) website: https://www.amphastar.com/
- Investor Relations - Amphastar Pharmaceuticals, Inc.: https://investors.amphastar.com/
- Yahoo Finance: https://finance.yahoo.com/quote/AMPH/
- MarketWatch: https://www.marketwatch.com/investing/stock/AMPH
Disclaimer: This information is intended for general knowledge and educational purposes only. It does not constitute professional financial advice, and you should consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amphastar P
Exchange | NASDAQ | Headquaters | Rancho Cucamonga, CA, United States |
IPO Launch date | 2014-06-25 | Co-Founder, President, CEO, Chief Scientific Officer & Director | Dr. Yongfeng Zhang Ph.D. |
Sector | Healthcare | Website | https://www.amphastar.com |
Industry | Drug Manufacturers - Specialty & Generic | Full time employees | 1761 |
Headquaters | Rancho Cucamonga, CA, United States | ||
Co-Founder, President, CEO, Chief Scientific Officer & Director | Dr. Yongfeng Zhang Ph.D. | ||
Website | https://www.amphastar.com | ||
Website | https://www.amphastar.com | ||
Full time employees | 1761 |
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.